These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 34376554)

  • 1. Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T.
    Dorff T; Hirasawa Y; Acoba J; Pagano I; Tamura D; Pal S; Zhang M; Waitz R; Dhal A; Haynes W; Shon J; Scholz M; Furuya H; Chan OTM; Huang J; Rosser C
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
    Small EJ; Lance RS; Gardner TA; Karsh LI; Fong L; McCoy C; DeVries T; Sheikh NA; GuhaThakurta D; Chang N; Redfern CH; Shore ND
    Clin Cancer Res; 2015 Sep; 21(17):3862-9. PubMed ID: 25925891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.
    Twardowski P; Wong JYC; Pal SK; Maughan BL; Frankel PH; Franklin K; Junqueira M; Prajapati MR; Nachaegari G; Harwood D; Agarwal N
    Cancer Treat Res Commun; 2019; 19():100116. PubMed ID: 30682445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
    Petrylak DP; Loriot Y; Shaffer DR; Braiteh F; Powderly J; Harshman LC; Conkling P; Delord JP; Gordon M; Kim JW; Sarkar I; Yuen K; Kadel EE; Mariathasan S; O'Hear C; Narayanan S; Fassò M; Carroll S; Powles T
    Clin Cancer Res; 2021 Jun; 27(12):3360-3369. PubMed ID: 33568344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Pachynski RK; Morishima C; Szmulewitz R; Harshman L; Appleman L; Monk P; Bitting RL; Kucuk O; Millard F; Seigne JD; Fling SP; Maecker HT; Duault C; Ramchurren N; Hess B; D'Amico L; Lacroix A; Kaiser JC; Morre M; Grégoire A; Cheever M; Yu EY; Fong L
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
    Subudhi SK; Siddiqui BA; Aparicio AM; Yadav SS; Basu S; Chen H; Jindal S; Tidwell RSS; Varma A; Logothetis CJ; Allison JP; Corn PG; Sharma P
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer.
    Heath EI; Thakur A; Chen W; Hwang C; Paller CJ; Cackowski FC; Boerner JL; Heilbrun L; Smith MP; Schalk DL; Schienschang A; Whitaker SA; Polend A; Smith D; Vaishampayan UN; Dickow B; Lum LG
    Cancer Res Commun; 2024 Jul; 4(7):1715-1725. PubMed ID: 38856749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
    Fong L; Morris MJ; Sartor O; Higano CS; Pagliaro L; Alva A; Appleman LJ; Tan W; Vaishampayan U; Porcu R; Tayama D; Kadel EE; Yuen KC; Datye A; Armstrong AJ; Petrylak DP
    Clin Cancer Res; 2021 Sep; 27(17):4746-4756. PubMed ID: 34108181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
    Petrylak DP; Vogelzang NJ; Chatta K; Fleming MT; Smith DC; Appleman LJ; Hussain A; Modiano M; Singh P; Tagawa ST; Gore I; McClay EF; Mega AE; Sartor AO; Somer B; Wadlow R; Shore ND; Olson WC; Stambler N; DiPippo VA; Israel RJ
    Prostate; 2020 Jan; 80(1):99-108. PubMed ID: 31742767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.
    GuhaThakurta D; Sheikh NA; Fan LQ; Kandadi H; Meagher TC; Hall SJ; Kantoff PW; Higano CS; Small EJ; Gardner TA; Bailey K; Vu T; DeVries T; Whitmore JB; Frohlich MW; Trager JB; Drake CG
    Clin Cancer Res; 2015 Aug; 21(16):3619-30. PubMed ID: 25649018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
    Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.
    Fong L; Carroll P; Weinberg V; Chan S; Lewis J; Corman J; Amling CL; Stephenson RA; Simko J; Sheikh NA; Sims RB; Frohlich MW; Small EJ
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25255802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
    Higano CS; Armstrong AJ; Sartor AO; Vogelzang NJ; Kantoff PW; McLeod DG; Pieczonka CM; Penson DF; Shore ND; Vacirca J; Concepcion RS; Tutrone RF; Nordquist LT; Quinn DI; Kassabian V; Scholz MC; Harmon M; Tyler RC; Chang NN; Tang H; Cooperberg MR
    Cancer; 2019 Dec; 125(23):4172-4180. PubMed ID: 31483485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
    BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
    Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
    Holl EK; McNamara MA; Healy P; Anand M; Concepcion RS; Breland CD; Dumbudze I; Tutrone R; Shore N; Armstrong AJ; Harrison M; Wallace JA; Wu Y; George DJ
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):588-592. PubMed ID: 30980027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
    Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
    Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
    Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
    Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
    J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.